Reaction Details Report a problem with these data
Target
Ret proto-oncogene
Ligand
BDBM13530
Substrate
n/a
Ki
>10000±n/a nM
Comments
PDSP_6372
Citation
 Melnick, JS; Janes, J; Kim, S; Chang, JY; Sipes, DG; Gunderson, D; Jarnes, L; Matzen, JT; Garcia, ME; Hood, TL; Beigi, R; Xia, G; Harig, RA; Asatryan, H; Yan, SF; Zhou, Y; Gu, XJ; Saadat, A; Zhou, V; King, FJ; Shaw, CM; Su, AI; Downs, R; Gray, NS; Schultz, PG; Warmuth, M; Caldwell, JS An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci U S A 103:3153-8 (2006) [PubMed]  Article 
Target
Name:
Ret proto-oncogene
Synonyms:
RET proto-oncogene tyrosine kinase receptor
Type:
Enzyme Catalytic Domain
Mol. Mass.:
3923.37
Organism:
Homo sapiens (Human)
Description:
Ret proto-oncogene 0 HUMAN::Q9UE13
Residue:
35
Sequence:
NASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQD
  
Inhibitor
Name:
BDBM13530
Synonyms:
4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide | CHEMBL941 | Gleevec | Imatinib | Imatinib, 21 | N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide | STI-571 | STI571 | US10906896, Cpd imatinib | US11649218, Example Imatinib | US11725005, Compound imatinib | US9255107, Imatinib | cid_5291 | imatinib-CD3 | med.21724, Compound 6
Type:
Small organic molecule
Emp. Form.:
C29H31N7O
Mol. Mass.:
493.6027
SMILES:
CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1
Structure:
Search PDB for entries with ligand similarity: